Chatswood serves the life and health insurance sector in New Zealand with market intelligence, data, and bespoke consulting services. Some of these are provided in conjunction with Quality Product Research Limited - a subsidiary that brings you Quotemonster.
We believe that good decisions are more likely to occur when we have good information about the market environment in which we operate. Intuitive leaps and creative decisions are always required, of course, but the more they are based on a firm foundation of observation, the better they tend to be.
Swiss Re on emerging risk insights
Swiss Re’s SONAR 2025: New emerging risk insights report identifies new or changed risks that could impact on insurers today and in the future.
Swiss Re’s SONAR 2025: New emerging risk insights report identifies new or changed risks that could impact on insurers today and in the future. The report highlights a range of emerging risks, with those most relevant to the life and health insurance sector being: declining consumer trust in institutions and the insurance industry; elevated levels of excess mortality; aging populations; extreme heat events; fungi-adaptations; harm caused by plastics; new technologies in healthcare delivery; rising consumption of ultra-processed foods; workforce gaps and skillset shortages. It’s an interesting read - we’ve picked out some things we think are particularly relevant to the New Zealand market.
With aging populations, fewer and later family formations could lead to less events (such as the birth of a child) that typically spur life insurance purchases.
While NZ is not subject to such extremes of temperature as in other parts of the world, a recent study estimated that 500 children under five are hospitalised for heat-related reasons each year in NZ . Currently 14 heat-related deaths occur in Auckland’s over-65 population annually – with climate change increasing the number of days exceeding 25C, we can expect the number of people dying from heat-related deaths to increase correspondingly.
With fungi adapting to warmer temperatures and the overuse of fungicides leading to more multi-drug-resistant fungal pathogens, there could be an increase in fungal infections and limited medical treatment options for those with fungal infections.
The potential health effects from micro- and nano-plastics and their additives are still being studied, but there is growing research on the negative impacts of plastics on human health.
Swiss Re highlight that innovations like GLP-1 weight-loss medications and the increasing uptake of these drugs should help reduce mortality in the future. Semaglutide (Wegovy/Ozempic) was approved for weight-loss use in New Zealand by Medsafe last month, though it is not Pharmac-funded.
The increasing availability and variety of AI and virtual health services should lead to healthier populations over time, by enabling early detection and preventative interventions. Personalised health monitoring and nudges towards healthier behaviour (a la AIA’s vitality product) will potentially reduce claim frequencies and lead to longer healthspans. Conversely, the digitalisation of medical records and other previously private health information, comes with greater data security and privacy risks.
Research has shown associations between high consumption of ultra-processed foods and elevated health risks, including obesity, type-2 diabetes, depression, cardiovascular disease and cancer.
An aging workforce will contribute to labour and skillset shortages in the healthcare field, which could lead to delays in medical treatment, under-diagnosis and sub-standard levels of care – leading to an increase in morbidity and mortality. Healthcare worker shortages have been in the news regularly in NZ and The Royal NZ College of General Practitioner’s 2022 workforce survey found 64% of specialist GP’s were intending to retire by 2032.
More news:
Fidelity Life roll out this year’s annual product re-accreditation
Financial Advice NZ community of Practice: Central District 17 July
Scheme of Arrangement between Foundation Life and policyholders approved
Russell Hutchinson writes of how insurers could improve awareness
Australian advisers change fee structure, higher revenue and profit
FMA cancel FAP licence – advice process, record-keeping, disclosures, and evidence of suitability all factors
The Financial Markets Authority has cancelled Filcare Services Limited’s Financial Advice Provider licence, at its request.
Filcare held a full financial advice provider licence, and they provided financial advice to approximately 1,800 retail clients, many of whom were migrant workers from the Filipino community. Its cancellation follows the termination of its distribution agreement with Fidelity Life Assurance Company Limited and AIA New Zealand Limited and the FMA’s inquiry into its affairs.
Filcare were found to have contravened its licence obligations by failing to:
keep adequate records in relation to advice given to its clients,
ensure its clients understood the financial advice they received,
exercise care diligence and skill when providing financial advice to its clients,
provide adequate disclosures relating to advice, and
demonstrate that recommendations made to clients were suitable.
From our perspective, that appears to indicate failures in a wide range of areas of the advice process. As a comparison business we are particularly concerned with the areas of care, diligence, and skill, and demonstrating suitability – which we help more than 1,100 advisers with.
FMA’s Head of Perimeter and Response Helena Lewis said
“…we observed that clients did not receive adequate nature and scope disclosures and were therefore unable to make an informed decision about whether to seek, obtain, or act on the advice.
We also found that Filcare advisers failed to demonstrate that the recommendations made to clients were suitable. As an example, for a vast majority of clients, the documentation on file lacked the requisite detail to clearly show how the selected levels of cover were determined, and that the recommendation matched the risk tolerance, financial situation, and needs and goals of the client.
In files concerning replacement advice, there was no evidence that clients were informed of the potential risks of replacing existing policies, such as losing benefits they might have otherwise received under original policies, or the likelihood of exclusions or limitations associated with changes in health, lifestyle, or occupation that have occurred since the original policy has been taken out.”
Filcare clients with concerns are able to complain to Financial Services Complaints Limited.
More news:
Insurers see 'unprecedented' claims levels
Financial Advice NZ webinar '4S Framework for Effective Client Communication' 25 July
Westpac announce strategic agreement with POLi to bring secure open banking payments to NZers
ASB offer assistance to customers affected by severe weather
Pharmac and Medsafe to explore the utilisation of AI to speed up their processes
Steve Wright argues that clients with ‘new’ health issues may still be better off with a different policy
Steve Wright argues that simply staying with an existing health insurer when a client has ‘new’ health issues, isn’t always the best advice.
Good Returns has an article where Steve Wright argues that simply staying with an existing health insurer when a client has ‘new’ health issues, isn’t always the best advice. He gives the example of a client with a current policy that doesn’t provide particular benefits (such as treatments not funded by Pharmac), which is effectively an exclusion on their policy. While the new health issues may not be covered, the client may still be better off switching to a reasonable alternative policy that includes other benefits the clients existing policy may effectively exclude them from.
We’d love to hear if you’ve got some examples like this you’d like to share.
More news:
Financial Advice NZ’s lunch with the Hon. Scott Simpson: A KiwiSaver Symposium is on 11 July
Policy holder claimed Southern Cross' treatment of menopause was discriminatory
Claire Sutton speaks about Asteron Life's company of the year awards
The Government will introduce legislation to ensure the health system is more accountable
Natalie McMurtry announced as Pharmac’s new Chief Executive, effective 15 September
Munich Re look at improving Cancer outcomes
As part of Munich Re’s Life Science Report 2025, they have investigated the projected impact of advances in cancer treatment and research. These advances will change how cancers are defined, prevented, diagnosed and treated and are expected to significantly improve cancer mortality.
As part of Munich Re’s Life Science Report 2025, they have investigated the projected impact of advances in cancer treatment and research. These advances will change how cancers are defined, prevented, diagnosed and treated and are expected to significantly improve cancer mortality.
Cancer is the leading cause of death among policyholders for most insurers worldwide, as such it demands investigation. Much progress has been made in the past couple of decades to improve cancer mortality, through both reducing cancer risk factors (such as the dramatic downturn in tobacco use) and better diagnosis and treatment. Mortality improvement trends are expected to accelerate as our understanding of cancer genetics are combined with artificial intelligence (AI).
AI will be used to both improve cancer risk prevention and diagnostics. AI analysis of an individual’s personal information such as health data, family history, genetic and epigenetic profiles, microbiome, living environment and exposure history, sometimes called a statistical biopsy, will give a better understanding of risk for a wide range of cancers. This could potentially allow for a personalised approach to risks, behaviours, and identification of which strategies may be most effective in addressing these factors.
Being able to diagnose cancer more accurately, and at earlier stages, should improve cancer mortality. AI has already led to refinements in imaging studies, and in blood, urine and tissue samples. AI can also be used to analyse the tumour’s genetic pattern, other associated biomarkers and an individual’s risk profile to allow for better prognosis and management approach. AI’s ability to recognise patters not apparent to humans will help with diagnostic tools such as imaging studies, pathologic specimen interpretation and photograph analysis.
More effective screening approaches will lead to earlier cancer diagnosis and improved cancer mortality. An important technology, ‘liquid biopsy’, is currently used to analyse fluids to look for markers indicating the presence of a cancer, typically used to detect residual cancer after treatment or recurrence. If a liquid biopsy test that can screen for multiple cancers in asymptomatic individuals could be brought to market at a price point where it is accessible to the masses, it would be a game changer. Though it would also raise concerns about over-diagnosis and surveillance bias, as some identified cancers may never post a significant mortality risk.
The combination of AI and genomic analysis of tumour cells and immune cells has led to the development of targeted treatments that exploit specific genetic patterns. These treatments are more precise and safer than chemotherapy, with the four key categories of therapies emerging being targeted monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines and adoptive cell immunotherapy.
With potential changes in how cancers are classified, product definitions will need to be modified. Instead of being classified based on their tissue of origin, it’s expected new cancer tests will be able to categorise cancers based on their underlying genetic causes – potentially leading to thousands of cancer subtypes.
Where previously terminal cancers become able to be managed and instead turn into chronic disease, there may be implications for living benefits products. Reduced mortality should be favourable for life insurances businesses, though the costs of more sophisticated, individualised cancer treatments may have a negative cost impact on health insurance businesses. Munich Re predict that advances in diagnosis and changes in diagnostic criteria are going to increase cancer incidence rates in the short term, but may decrease critical illness rates if major advances in cancer prevention are realised.
AI will also have implications for underwriting. AI-based diagnosis is likely to be more accurate and predictive than current methods, with fewer false positive and false negative results, enabling risk to be better assessed. Better monitoring post-cancer treatment will mean recurrence risk can be more accurately assessed too.
More news:
Southern Cross Health Trust to fund salaries of nursing positions at City Missions
Kiwi advisers believe AI could help improve advice delivery
Pharmac to fund or widen access to three treatments, including for skin cancer, from 1 June 2025
Proposed changes to Health and Safety Laws
We take a look at the proposed changes to Health and Safety laws, whereby the government wants to reduce compliance costs and provide greater certainty for businesses.
You may have seen the proposed changes to Health and Safety laws, whereby the government wants to reduce compliance costs and provide greater certainty for businesses. Bell Gully have a good summation of the proposed reforms here, but basically the Government is endeavouring to reduce the compliance burden, clarify health and safety duties (including limiting obligations for small, low-risk businesses) and clarify the distinction between governance and operational health and safety responsibilities.
There are many opposing points of view on the changes. Council of Trade Unions president Richard Wagstaff has said
"It's disappointing to see the minister has ignored the widespread consensus on what New Zealand needs to do to improve its poor track record and instead has chosen to carve out small businesses from good health and safety practices.
Exempting small businesses from best practice health and safety makes no sense when we know that small business are riskier and need more support."
Institute of Directors general manager Guy Beatson said
"Clarifying that boards are accountable for risk management and safety culture - not hands-on management - will mean directors can better focus on their core governance role without inadvertently overstepping."
Mike Cosman, chair of the Institute of Safety Management said
"The reforms are focused instead on costs to businesses of prevention and not the much greater costs of harm.
This seems to be looking through the wrong end of the telescope to us because the cost of our poor health and safety record is north of $4.9 billion per year to say nothing of the impact on workers and their families."
Russell Hutchinson has taken a look at the proposed regulations and put in his two cents.
As a country we have a not-terrible, but not-so-good track record on health and safety. One measure is fatal accidents, here I have selected countries we often use in comparisons:
Clearly, we are not as bad as, say, the United States. If we delved into that we would see significant variation on a state-by-state basis – but let’s not worry about that for now. Compared to Australia, for roughly every three people who die in a workplace accident there, four will die here. Not so good. What’s surprising is how well the UK performs – better than France and much of the EU, and better than Japan, places I normally consider to be better organised and more prescriptive in terms of employee protections. Not so! I like it when we find good data which challenges my pre-existing view. It’s a reward for paying attention to the data.
Are the proposed changes to governance liability right or wrong? One argument could be that by reducing liability on directors the workplace will become less safe. Another view is that by ensuring we place responsibility on the people who are closest to the problem we will better target the point at which better decisions can be made. Probably we will not know which until we have seen this operate for some time. Progress always seems to be so slow. Incentives also count – and the role of ACC, which has many benefits to our economy, also has some negative effects, somewhat masking the price signal in this case. I wonder if that will also get talked about.
More news:
Russell Hutchinson explains Non-Pharmac medicines coverage
AIA introducing a new excess option to AIA Private Health
AIA have updated Rules to Reinstate Policies
FSC Workplace Savings Half-Yearly Function 2025 is on 21 May
Financial Advice NZ are holding a 'Community of Practice: Central District' on 29 April
How to reduce chronic inflammation in your body
Eating well and getting regular exercise are most effective longevity tactics
Report finds deposit insurance scheme could see deposit interest rates fall significantly
Commerce Commission puts banks’ clawbacks, conversions and disincentives under scrutiny
Fidelity Life financial strength rating reaffirmed
Fidelity Life has had its A- (Excellent) financial strength rating affirmed by AM Best.
Fidelity Life, New Zealand’s largest locally owned life insurer, had its A- (Excellent) financial strength rating affirmed by AM Best. The outlook for the rating is stable, and according to AM Best, reflects Fidelity Life’s ‘very strong’ balance sheet.
Fidelity Life Chief Financial Officer Simon Pennington said
“This A- rating from AM Best is a reassuring endorsement of our business's financial health and stability. As a life insurer, this independent assessment gives advisers confidence in partnering with us, and for customers, it ensures peace of mind in our ability to pay claims.”
More news:
Brendan Boyle starts as Pharmac’s Acting Chief Executive on Monday 31 March
Westpac-McDermott Miller Consumer Confidence Index falls to 89.2 in March
Legal and regulatory update for the life and health insurance sector
Assistant Governor Kate Kolich leaving RBNZ; FMA publishes speech by Craig Stobo to the Institute of Directors and New Zealand Initiative; Annual review of PHARMAC published; FSC publish their March 2025 Regulatory Forecast; FIU release latest National Risk Assessment, which RBNZ welcomes; FMA considering a class exemption to provide relief from certain reporting, audit and assurance obligations.
11 Mar 2025 - Assistant Governor/General Manager Information, Data and Analytics Kate Kolich will be leaving RBNZ at the end of March 2025. https://www.rbnz.govt.nz/hub/news/2025/03/general-manager-information-data-and-analytics-departs
13 Mar 2025 - The FMA publishes speech by Craig Stobo to the Institute of Directors and New Zealand Initiative. https://www.fma.govt.nz/library/speeches-and-presentations/speech-by-craig-stobo-to-the-institute-of-directors-and-nz-initiative/
13 Mar 2025 - Final report on the 2023/24 Annual review of the Pharmaceutical Management Agency (PHARMAC) was published by the Health Committee. https://selectcommittees.parliament.nz/v/6/c493f47b-6545-4a41-1243-08dd61b37e3c
14 Mar 2025 - The FSC publish their March 2025 Regulatory Forecast, available to FSC members.
17 Mar 2025 - The Police’s Financial Intelligence Unit have released the latest National Risk Assessment for 2024. https://www.police.govt.nz/sites/default/files/publications/fiu-nra-2024.pdf
17 Mar 2025 - The RBNZ has welcomed the release of the latest National Risk Assessment (NRA) from Police’s Financial Intelligence Unit. The report assesses threat and sectoral vulnerability, exploring their impact on money laundering and terrorism financing risk and proliferation financing in New Zealand. https://www.rbnz.govt.nz/hub/news/2025/03/reserve-bank-supports-the-release-of-the-new-zealand-national-risk-assessment
17 Mar 2025 - The FMA are considering a class exemption to provide relief from certain reporting, audit and assurance obligations under the Financial Markets Conduct Act 2013 and the Financial Markets Conduct Regulations 2014 for registered Managed Investment Schemes that are in wind-up. Consultation closes 12 May 2025. https://www.fma.govt.nz/business/focus-areas/consultation/consultation-proposed-reporting-audit-and-assurance-exemptions-for-schemes-in-wind-up/
Chubb Life NZ appoints new Head of Claims
Chubb Life NZ has announced that Reeta Anthony has been appointed as its new Head of Claims, effective immediately.
Chubb Life NZ has announced that Reeta Anthony has been appointed as its new Head of Claims, effective immediately. Anthony will report to Debbie Eyre, Chief Operating Officer, and will be responsible for the strategic delivery of the claims proposition. Anthony has over 25 years of financial services experience and expertise and was most recently Head of Claims at Fidelity Life.
More news:
Kate Jorgensen has been appointed to the Board of Southern Cross Medical Care Society.
ASB's NPAT for the six months to December 2024 was $763 million
Pharmac announces decision to fund medicines for a further five health conditions
FSC’s FAP round table breakfast with the FMA
Several of our team attended the Financial Services Council’s FAP round table breakfast with the Financial Markets Authority last month.
Quality Product Research are sponsors of the Financial Services Council’s (FSC's) FAP round table breakfast with the Financial Markets Authority (FMA) last month. Several of our team were there, including Aneel Ravji, AdviceTech Lead, Kelly Pulham, National Partnerships Lead, and Russell Hutchinson, Research Director.
The FMA covered how the new regime is working, approaches to enforcement and other initiatives. Attendees were taken through the background and given an overview of the Conduct of Financial Institutions (CoFI) regime. Other topics included observations on remediations, fair conduct programmes and an overview of the CoFI intermediated distribution guide. Russell Hutchinson facilitated a lively Q&A session.
Here's a few snaps from the day. We highly recommend you attend the FSC round tables if you get the chance, they always make for an interesting and engaging start to the day.
Pictured, from the Financial Markets Authority, from left to right: Michael Hewes, Director, Deposit Taking, Insurance and Advice; Anna Jared, Technical Specialist – Deposit Taking, Insurance & Advice; Kyla Bottriell, Senior Adviser, External Relations; and Romil Ghelani, Head of Financial Advice
Russell Hutchinson, Director at Quality Product Research Ltd, facilitates a Q&A session.
Apex Advice Group and OPM Insurance merge
Apex Advice Group and OPM Insurance have announced their strategic merger.
Apex Advice Group and OPM Insurance have announced their strategic merger. OPM Insurance was founded by Oliver Pereira 17 years ago.
Craig Mulholland, Chief Executive of Apex Advice Group, said
“We are delighted to welcome OPM Insurance into the Apex Advice Group family. This partnership strengthens our position as a leading financial advisory firm and allows us to expand our reach and offerings. We are confident this will benefit our clients and drive continued growth.”
More news:
Pharmac funding new HRT gel to aid Kiwi women with menopause symptoms